Literature DB >> 23123818

Translational implications of novel findings in cancer cachexia: the use of metabolomics and the potential of cardiac malfunction.

Hirak Der-Torossian1, Christine G Gourin, Marion E Couch.   

Abstract

PURPOSE OF REVIEW: Cancer cachexia is a complex metabolic syndrome that manifests as a progressive wasting disorder. Recent findings have substantially improved our understanding of this unique entity shedding light on a potentially significant and overlooked morbidity in the form of cardiac functional changes that may occur in tandem with cachexia. Moreover, recent technological advances, such as with the application of metabolomic analysis, have yielded a better understanding of the metabolic changes that accompany this condition. RECENT
FINDINGS: Recent evidence from murine studies indicates that the skeletal muscle wasting in cancer cachexia may be accompanied by cardiac muscle wasting. This decreased heart weight is accompanied by functional cardiac changes, which are suggestive of congestive heart failure. In addition, metabolomic analysis of body fluids and tissues distinguishes cancer cachexia's unique metabolic fingerprint as a separate entity, different from healthy controls, tumor burden, caloric restriction, and aging. It also gives insight into the metabolic changes that occur in the affected tissues such as the Warburg effect that is not often described in muscle.
SUMMARY: Translational investigations into potential cardiac malfunction in cancer patients and metabolomic analyses of patients' sera and tissues are warranted to determine whether these changes are upheld in humans.

Entities:  

Mesh:

Year:  2012        PMID: 23123818     DOI: 10.1097/SPC.0b013e328359b695

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  7 in total

Review 1.  MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review).

Authors:  Xin Li; Lidong Du; Qiang Liu; Zhong Lu
Journal:  Exp Ther Med       Date:  2022-05-16       Impact factor: 2.751

2.  Establishment and characterization of a novel murine model of pancreatic cancer cachexia.

Authors:  Katherine A Michaelis; Xinxia Zhu; Kevin G Burfeind; Stephanie M Krasnow; Peter R Levasseur; Terry K Morgan; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-07-20       Impact factor: 12.910

3.  Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study.

Authors:  Mónica Patricia Cala; María Teresa Agulló-Ortuño; Elena Prieto-García; Carolina González-Riano; Lucía Parrilla-Rubio; Coral Barbas; Carmen Vanesa Díaz-García; Antonia García; Cristina Pernaut; Jorge Adeva; María Carmen Riesco; Francisco Javier Rupérez; Jose Antonio Lopez-Martin
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-02-20       Impact factor: 12.910

Review 4.  Nonmuscle Tissues Contribution to Cancer Cachexia.

Authors:  Josep M Argilés; Britta Stemmler; Francisco J López-Soriano; Silvia Busquets
Journal:  Mediators Inflamm       Date:  2015-10-07       Impact factor: 4.711

5.  Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.

Authors:  Seyyed M R Kazemi-Bajestani; Harald Becher; Konrad Fassbender; Quincy Chu; Vickie E Baracos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-03-14       Impact factor: 12.910

6.  Formoterol in the treatment of experimental cancer cachexia: effects on heart function.

Authors:  Míriam Toledo; Jochen Springer; Sílvia Busquets; Anika Tschirner; Francisco J López-Soriano; Stefan D Anker; Josep M Argilés
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-08-29       Impact factor: 12.910

Review 7.  Review of Mechanisms and Treatment of Cancer-Induced Cardiac Cachexia.

Authors:  Vignesh Vudatha; Teja Devarakonda; Christopher Liu; Devon C Freudenberger; Andrea N Riner; Kelly M Herremans; Jose G Trevino
Journal:  Cells       Date:  2022-03-18       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.